Latest on reverberations of abortion pill ruling; Biotech venture funding dips; Novo Nordisk dives into diabetes cell therapy; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Be sure to check our website over the weekend if you’re interested in cancer research — Nicole DeFeudis and Katherine Lewin are in Orlando reporting the latest update out of the AACR conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.